OKYO Pharma Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OKYO research report →
About the company
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain.
- CEO
- Robert J. Dempsey
- IPO
- 2022
- Employees
- 3
- HQ
- London, GB
Price Chart
- Market Cap
- $60.24M
- P/E
- -14.36
- P/S
- 0.00
- P/B
- -17.20
- EV/EBITDA
- -5.86
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 102.92%
- ROIC
- 154.22%
- Revenue
- $0 · 0.00%
- Net Income
- $-4,706,292 · 72.03%
- EPS
- $-0.12 · -19900.00%
- Op Income
- $-7,188,875
- FCF YoY
- 80.91%
- 52W High
- $3.35
- 52W Low
- $1.42
- 50D MA
- $1.60
- 200D MA
- $1.91
- Beta
- 0.02
- Avg Volume
- 67.06K
Get TickerSpark's AI analysis on OKYO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 10, 30 | Mantelli Flavio | other | 187,500 |
| Jun 8, 26 | Denoyer Bernard | other | 3,500 |
| Jun 8, 26 | BRANCACCIO JOHN P | other | 6,500 |
| Jun 8, 26 | Simon Willy Jules | other | 6,500 |
| Jun 8, 26 | Shah Keeren Rameshchandra | other | 40,000 |
| Jun 8, 26 | CERRONE GABRIELE M | other | 300,000 |
| Mar 25, 29 | Denoyer Bernard | other | 3,750 |
| Mar 14, 27 | Denoyer Bernard | other | 769 |
| Mar 13, 27 | Denoyer Bernard | other | 3,333 |
| Jan 29, 28 | Denoyer Bernard | other | 1,205 |
Our OKYO coverage
Recent articles, reports, and earnings notes.
No research on OKYO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OKYO report →Similar companies
Peers in the same neighborhood.